Search

Displaying results 3371 - 3380 of 4231 in total
  1. Drug

    Bifidobacterium Longum Infantis 35624

    go.drugbank.com/drugs/DB17871
    Experimental

    Bifidobacterium Longum Infantis 35624 is a probiotic being investigated for the treatment of gastrointestinal disorders, such as Crohn's disease and irritable bowel syndrome.[A259872, A259877]

  2. Drug

    Avanafil

    go.drugbank.com/drugs/DB06237
    Approved

    Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both sildenafil and vardenafil but l...

  3. Drug

    Ceftizoxime

    go.drugbank.com/drugs/DB01332
    ApprovedWithdrawn

    A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram...

  4. Drug

    Cositecan

    go.drugbank.com/drugs/DB05806
    Investigational

    Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.

  5. Drug

    AGuIX

    go.drugbank.com/drugs/DB18189
    Investigational

    It is under development as a radiosensitizer to be used during radiation treatment of malignant glioma.

  6. Drug

    Follitropin

    go.drugbank.com/drugs/DB00066
    ApprovedInvestigational

    The nomenclature “beta” differentiates it from another recombinant human FSH product that was marketed earlier as follitropin alpha. … Follitropin is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta

  7. Drug

    Paquinimod

    go.drugbank.com/drugs/DB13118
    Investigational

    The autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses.

  8. Drug

    Idarucizumab

    go.drugbank.com/drugs/DB09264
    Approved

    As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease

  9. Drug

    Sage oil

    go.drugbank.com/drugs/DB11199
    ApprovedNutraceutical

    Essential oil has been traditionally used in medicine for the relief of pain and the treatment of inflammation and infections, as it is reported to exhibit carminative, antispasmodic, antiseptic, and astringent

  10. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    This approval is based on the positive results obtained from the Phase 3 studies ADvocate 1 and ADvocate 2, where nearly 80% of patients taking lebrikizumab either as monotherapy or combination therapy